[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100578155":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":31,"locations":40,"responsibleParty":118,"collaborators":120,"id":124,"slug":35,"hasResults":125,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":35,"eligibilityCriteria":129,"healthyVolunteers":125,"sex":130,"minAge":131,"maxAge":35,"enrollmentInfo":132,"targetDuration":35,"studyType":135,"phases":136,"briefSummary":138,"conditions":139,"keywords":141,"overallStatus":43,"whyStopped":35,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":156},{"fullName":5,"class":6},"Memorial Sloan Kettering Cancer Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"DCOI naïve","EXPERIMENTAL","Will receive the standard dose of sotorasib.",[13],"Drug: Sotorasib",{"label":15,"type":16,"description":17,"interventionNames":18},"Progressed on the DCOI","ACTIVE_COMPARATOR","Will continue to receive the sotorasib dose they were previously receiving, according to their doctor's instruction.",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Sotorasib","Enrolled patients will be administered DCOI at the FDA-recommended dose or continued on the DCOI at the discretion of the treating Oncologist per standard of care",[9,15],[26],"AMG 510",[28],{"name":29,"affiliation":5,"role":30},"Nelson Moss, MD","PRINCIPAL_INVESTIGATOR",[32,37],{"name":29,"role":33,"phone":34,"phoneExt":35,"email":36},"CONTACT","212-639-7075",null,"mossn@mskcc.org",{"name":38,"role":33,"phone":39,"phoneExt":35,"email":35},"Cameron Brennan, MD","212-639-8268",[41,56,67,79,86,97,107],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)","RECRUITING","Basking Ridge","New Jersey","07920","United States",{"type":49,"coordinates":50},"Point",[51,52],-74.54932,40.70621,{"lat":52,"lon":51},[55],{"name":29,"role":33,"phone":34,"phoneExt":35,"email":35},{"facility":57,"status":43,"city":58,"state":45,"zip":59,"country":47,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"Memorial Sloan Kettering Monmouth (Limited Protocol Activities)","Middletown","07748",{"type":49,"coordinates":61},[62,63],-74.11709,40.39428,{"lat":63,"lon":62},[66],{"name":29,"role":33,"phone":34,"phoneExt":35,"email":35},{"facility":68,"status":43,"city":69,"state":70,"zip":71,"country":47,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Memorial Sloan Kettering Commack (Limited Protocol Activities)","Commack","New York","11725",{"type":49,"coordinates":73},[74,75],-73.29289,40.84288,{"lat":75,"lon":74},[78],{"name":29,"role":33,"phone":34,"phoneExt":35,"email":35},{"facility":80,"status":43,"city":69,"state":70,"zip":71,"country":47,"cosmosGeoPoint":81,"geoPoint":83,"contacts":84},"Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities)",{"type":49,"coordinates":82},[74,75],{"lat":75,"lon":74},[85],{"name":29,"role":33,"phone":34,"phoneExt":35,"email":35},{"facility":87,"status":43,"city":88,"state":70,"zip":89,"country":47,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"Memorial Sloan Kettering West Harrison (Limited Protocol Activities)","Harrison","10604",{"type":49,"coordinates":91},[92,93],-73.71263,40.96899,{"lat":93,"lon":92},[96],{"name":29,"role":33,"phone":34,"phoneExt":35,"email":35},{"facility":98,"status":43,"city":70,"state":70,"zip":99,"country":47,"cosmosGeoPoint":100,"geoPoint":104,"contacts":105},"Memorial Sloan Kettering Cancer Center (All Protocol Activities)","10065",{"type":49,"coordinates":101},[102,103],-74.00597,40.71427,{"lat":103,"lon":102},[106],{"name":29,"role":33,"phone":34,"phoneExt":35,"email":35},{"facility":108,"status":43,"city":109,"state":70,"zip":110,"country":47,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"Memorial Sloan Kettering Nassau (Limited Protocol Activities)","Uniondale","11553",{"type":49,"coordinates":112},[113,114],-73.59291,40.70038,{"lat":114,"lon":113},[117],{"name":29,"role":33,"phone":34,"phoneExt":35,"email":35},{"type":119,"investigatorFullName":35,"investigatorTitle":35,"investigatorAffiliation":35,"oldNameTitle":35,"oldOrganization":35},"SPONSOR",[121],{"name":122,"class":123},"Amgen","INDUSTRY","100578155",false,"NCT06807619","A Study of Sotorasib in People With Brain Tumors","BrainMet ADePPT (Anticancer Drug Penetration Platform Trial)","Inclusion Criteria:\n\n* Adult patients ≥ 18 years of age with one or more brain tumors planned for neurosurgical resection\u002Fbiopsy\n* Patients with concomitant leptomeningeal metastasis are eligible provided they have parenchymal brain neoplastic disease requiring resection\u002Fbiopsy\n* For all cohorts: no limit on prior CNS radiation or systemic therapyKPS ≥ 60\n* Life expectancy \\>12 weeks\n* Adequate treatment washout period from prior therapies to allow recovery from any prior treatment-related toxicities before enrollment in the judgment of the Investigator\n* Adequate bone marrow, renal, hepatic, and coagulation parameters (obtained ≤7 days prior to the first day of study treatment):\n\n  * Absolute neutrophil count (ANC) ≥1.0 × 10\\^3\u002FμL (granulocyte-colony stimulating factor administration is not allowed within 1 week prior to C1D1)\n  * Platelet count ≥10.0x10\\^4\u002FμL. Note: Participants requiring ongoing transfusions or growth factor support to maintain platelet count ≥10.0x10\\^4\u002FμL are not eligible. (Platelet transfusion is not allowed within 1 week prior to C1D1)\n  * Hemoglobin ≥ 7.0 g\u002FdL (≥ 8 g\u002FdL in gastric cancer \u002F gastroesophageal cancer indications). Note: Participants requiring ongoing transfusions or growth factor support to maintain hemoglobin ≥8.0 g\u002FdL are not eligible (Red blood cell transfusion is not allowed within 1 week prior to C1D1)\n  * Creatinine clearance ≥30 mL\u002Fmin, as calculated using the Cockcroft-Gault equation\n  * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 × upper limit of normal (ULN) (\\\u003C5x ULN in participants with liver metastases)\n  * Total bilirubin ≤1.5 × ULN) if no liver metastases or \\\u003C3 × ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver metastases at baseline\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to study treatment or any of the study drug excipients. For patients who are allergic to gadolinium-based agents may receive premedication as per institutional protocol or imaged without contrast at the discretion of the Principal Investigator; reactions will be managed per standard institutional protocol\n* Multiple primary malignancies within 3 years, with the exception of:\n\n  * adequately resected non-melanoma skin cancer\n  * carcinoma in situ of the cervix\n  * Smoldering pre-malignant or malignant conditions with minimal concern for CNS or extracranial progression during treatment such as CLL or MGUS based on the assessment of the treating provider\n  * curatively treated in-situ disease\n  * other solid tumors curatively treated\n  * for patients with metastatic breast cancer: contralateral breast cancer","ALL","18 Years",{"count":133,"type":134},16,"ESTIMATED","INTERVENTIONAL",[137],"PHASE1","The researchers are doing this study to find out how effective sotorasib is at getting into KRAS G12C+ brain tumors. The researchers will also find out whether sotorasib is a safe and effective treatment for people undergoing surgical resection of KRAS G12C+ metastatic brain tumors, and do tests that show how the body absorbs, distributes, and gets rid of sotorasib.",[140],"Brain Tumor",[142,143,144,145,146],"SOTORASIB","KRAS G12C","CNS-BRAIN","Advanced","24-111","2026-05-21",{"date":149,"type":150},"2026-05-22","ACTUAL",{"date":152,"type":150},"2025-01-29",{"date":154,"type":134},"2028-01",{"name":5,"class":6},7]